Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.27 - $11.5 $434,138 - $18.5 Million
-1,607,921 Reduced 96.67%
55,445 $472,000
Q4 2021

Feb 14, 2022

BUY
$8.95 - $16.88 $14.9 Million - $28.1 Million
1,663,366 New
1,663,366 $16.6 Million

About Finch Therapeutics Group, Inc.


  • Ticker FNCH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,688,400
  • Market Cap $525M
  • Description
  • Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...
More about FNCH
Track This Portfolio

Track Avenir Management Company, LLC Portfolio

Follow Avenir Management Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avenir Management Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avenir Management Company, LLC with notifications on news.